Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOpredict-EGFR: Preoperative Amivantamab in NSCLC
NCT06784791Phase 2Recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Universitätsmedizin Essen. Started Nov 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06784791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784791.